Elevar Therapeutics
Michael Palucki has extensive work experience in the pharmaceutical industry. Michael is currently serving as the Vice President of Manufacturing at Elevar Therapeutics since May 2022. Prior to this role, they worked at Venatorx Pharmaceuticals, Inc. as the Executive Director CMC Team Leader, Development and Supply from 2018 to 2022.
Michael'sprevious experience includes various roles at Merck. As the Director, Portfolio and Product Development Lead, they were responsible for driving late lifecycle product development and collaborating with external partners and various internal functions. Michael also served as the Director, Project Team Leader and Manager, CMC Project Leadership Group, where they were responsible for aligning and implementing CMC late-stage development-commercial strategy. Additionally, they worked as the Associate Director/Senior Investigator at Merck Research Labs, leading the Chemistry arm of the Basic Pharmaceutical Sciences organization.
Overall, Michael Palucki has expertise in manufacturing, development, supply, project management, and chemistry within the pharmaceutical industry.
Michael Palucki has a Doctor of Philosophy (PhD) in Organic Chemistry from Harvard University. Michael also has a Post Doc in Chemistry from the Massachusetts Institute of Technology. Additionally, they hold a certification in Lean Six Sigma Green Belt. No information is available regarding the start and end years, the institution from which the certification was obtained, or the month and year the certification was obtained.
This person is not in any offices
Elevar Therapeutics
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.